Diagnostic Imaging's Weekly Scan: October 8-October 14

Currently being evaluated in a phase 2b clinical trial, the 18F-RAD101 PET imaging agent garnered the FDA’s fast track designation for distinguishing between recurrent disease and treatment impact for brain metastases derived from solid tumors.

In a new podcast, Satoshi Minoshima, M.D., Ph.D., and James Williams, Ph.D., share their insights on the recently updated appropriate use criteria for amyloid PET and tau PET in patients with mild cognitive impairment.

An alternative to an open neurosurgical approach, the Visualase V2 MRI-Guided Laser Ablation System reportedly utilizes laser interstitial thermal therapy (LITT) for targeted soft tissue ablation in patients with brain tumors and focal epilepsy.

An interview with two experts to discuss newly released guidance for using standardized MRI protocols for patients with this condition.

A partial response rate to neoadjuvant chemotherapy on mid-treatment MRI preceded a higher pathologic complete response (pCR) in 61.5 percent of women with triple-negative breast cancer, according to research presented at the American Society of Clinical Oncology (ASCO) conference.

Assessing the simulated use of AI-generated suspicion scores for determining whether one should continue with full MRI or shift to an abbreviated MRI, the authors of a new study noted comparable sensitivity, specificity, and positive predictive value for biopsies between the MRI approaches.